Mirum Pharmaceuticals Stock Price, News & Analysis

On February 10, 2022, Mirum Pharmaceuticals granted inducement awards to two new employees, including non-qualified stock options for 14,200 shares and 7,100 restricted stock units (RSUs) under its 2020 Inducement Plan. The stock options have an exercise price of $22.41, the closing price on the grant date, and vest over four years. The RSUs vest over three years. Mirum, a biopharmaceutical company, focuses on treatments for rare diseases, with an approved drug LIVMARLI for cholestatic pruritus and a late-stage pipeline for liver diseases.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) will participate in the SVB Leerink 11th Annual Global Healthcare Conference from February 14-18, 2022. The company is scheduled to present on February 16, 2022, at 4:20 p.m. ET. Mirum is focused on developing treatments for rare diseases, including its approved drug LIVMARLI® for Alagille syndrome. The company also has investigational treatments in clinical trials for various liver diseases, demonstrating its commitment to improving patient outcomes in this field.

Mirum Pharmaceuticals (NASDAQ: MIRM) announced an estimated net product revenue of $3.0 million for LIVMARLI in Q4 2021. The company reported cash and equivalents totaling $261.5 million as of December 31, 2021. CEO Chris Peetz highlighted a strong market entry for LIVMARLI, the only FDA-approved treatment for cholestatic pruritus in Alagille syndrome. Future milestones include expanding access internationally and upcoming trial data releases.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) reported that on January 10, 2022, its Compensation Committee granted inducement awards of stock options and restricted stock units to five new employees. The inducement awards consist of 51,700 stock options at an exercise price of $15.50 per share and 7,150 restricted stock units. The stock options vest over four years, while the RSUs vest over three years. These awards aim to attract talent to support Mirum's mission in treating rare diseases, with a focus on the company's approved medication LIVMARLI™ and ongoing clinical trials for other treatments.

Mirum Pharmaceuticals (MIRM) will present at the virtual J.P. Morgan Healthcare Conference from January 10-13, 2022. CEO Chris Peetz will share insights on the company’s strategy and updates on LIVMARLI™ (maralixibat), an oral solution approved for treating cholestatic pruritus in Alagille syndrome patients aged one and older. The presentation is scheduled for January 11 at 1:30 p.m. ET. Mirum will also host a fireside chat at the H.C. Wainwright Virtual BIOCONNECT 2022 Conference. Further information can be found on their website.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) has been added to the NASDAQ Biotechnology Index, effective December 20, 2021. This index includes NASDAQ-listed companies in the biotechnology and pharmaceutical sectors that meet specific eligibility criteria. Mirum is focused on treating rare liver diseases, with its approved drug LIVMARLI™ for cholestatic pruritus in Alagille syndrome patients. The company is also developing investigational treatments and has acquired options for gene therapies targeting PFIC types 2 and 3.

Mirum Pharmaceuticals presented new analyses from clinical studies of LIVMARLI™ at the NASPGHAN Annual Meeting. The studies focused on children with Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC2). In the ICONIC study, 74% of patients showed improvement in pruritus, correlating with enhancements in health-related quality of life (HRQoL) measures, including fatigue and sleep disturbances. Additionally, patients with PFIC2 achieving serum bile acid response also noted significant HRQoL improvements. These findings highlight LIVMARLI's potential in treating rare liver diseases.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) announced the presentation of five posters on LIVMARLI™ (maralixibat) at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Annual Meeting from December 12-18, 2021. Key studies highlight the treatment's impact on health-related quality of life for patients with Alagille syndrome and BSEP deficiency. The abstracts are accessible via the NASPGHAN website, and LIVMARLI is recognized as a breakthrough therapy for certain cholestatic liver diseases.

Mirum Pharmaceuticals (Nasdaq: MIRM) will participate in two upcoming virtual investor conferences. The Piper Sandler 33rd Annual Virtual Healthcare Conference on November 30, 2021, will include a fireside chat available from November 22. The 4th Annual Evercore ISI HealthconX Conference is scheduled for December 2, with a fireside chat at 3:30 p.m. ET. Mirum specializes in treatments for rare liver diseases, including LIVMARLI (maralixibat), approved for cholestatic pruritus in Alagille syndrome. The company is developing investigational treatments for various liver conditions.